儿童和青少年患有发作性偏头痛的freemanezumab
Andrew D Hershey1, Christina L Szperka2,3, Piero Barbanti4,5
1Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati.
The New England journal of medicine
|January 14, 2026
概括
与安慰剂相比,弗雷曼祖马布在患有偶发性偏头痛的儿童和青少年中显著减少了偏头痛和头痛天数. 注射部位红血是观察到的最常见的副作用.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 针对色素基因相关的单克隆抗体Fremanezumab已被批准用于成人偏头痛预防.
- 需要随机对照试验来确定儿科患者群体的疗效和安全性.
研究的目的:
- 评估弗雷曼尼祖马布在6至17岁儿童和青少年中预防情节性偏头痛的疗效和安全性.
主要方法:
- 一个随机的,安慰剂对照试验,涉及237名参与者 (6-17岁) 患有偶发性偏头痛.
- 参与者每月接受弗雷曼祖马布 (120毫克或225毫克根据体重) 或安慰剂的皮下注射,持续3个月.
- 主要终点:平均每月偏头痛天数的变化;次要终点包括头痛天数和偏头痛减少50%.
主要成果:
- 弗雷曼祖马布每月的偏头痛日减少了2.5天,而安慰剂减少了1.4天 (P=0.02).
- 47.2%的弗雷曼尼祖马布接受者在偏头痛日减少了50%或更多,而安慰剂接受者为27.0% (P=0.002).
- 注射部位红血是最常见的不良事件 (9.8%与安慰剂5.4%).
结论:
- 弗雷曼祖马布在减少儿童和青少年的偏头痛和头痛天数方面表现出比安慰剂更大的疗效.
- 注射部位红是最常见的不良事件.
- 需要进行进一步的长期研究,以充分评估弗雷曼尼祖马布在这个年龄组的疗效和安全性.
更多相关视频
10:393D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
18.7K
10:22Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
Published on: December 6, 2016
21.0K
相关概念视频
01:14Antiepileptic Drugs: Glutamate Antagonists
898
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
898
01:20Antiepileptic Drugs: Potassium Channel Activators
635
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
635
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
212
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212